zurück

Melphalan flufenamide (multiple myeloma, ≥ 3 prior therapies, in combination with dexamethasone)

 

Subject:

  • Active Substance: Melphalan flufenamide 
  • Name: Pepaxti®
  • Therapeutic area: Multiple myeloma
  • Pharmaceutical company: Oncopeptides AB

 

Time table:

  • Start: 01.10.2022
  • Final decision by G-BA: 16.03.2023

 

Final decision:

  • No additional benefit proved